Sesamin, the major
lignan found in sesame, has been shown to increase
vitamin E levels by inhibiting its metabolism via the
cytochrome P450 isozyme CYP4F2. CYP4F2 and CYP4A11 are the predominant human
isoforms that synthesize
20-hydroxyeicosatetraenoic acid (20-HETE) from
arachidonic acid. Considerable evidence suggests that
20-HETE may play a role in the pathogenesis of
hypertension. We hypothesized that
sesamin could be an inhibitor of
20-HETE synthesis. This study investigated the effects of
sesamin on
20-HETE synthesis in vitro and the effect of sesame supplementation on plasma and urinary
20-HETE concentrations in humans. Human microsomes were used to investigate the potency and selectivity of
sesamin inhibition of
20-HETE synthesis.
Sesamin inhibited human renal and liver microsome
20-HETE synthesis with IC50 <20 micromol/L. It was selective toward CYP4F2 (IC50: 1.9 micromol/L) and had reduced activity toward CYP4A11 (IC50: >150 micromol/L), as well as
cytochrome P epoxygenation of
arachidonic acid (IC50: >50 micromol/L). In a randomized, controlled crossover trial,
overweight men and women (n=33) consumed 25 g/d of sesame (approximately 50 mg/d of sesame
lignan) or an isocaloric matched control for 5 weeks each. Relative to control, sesame supplementation resulted in a 28% decrease in plasma and a 32% decrease in urinary
20-HETE (P<0.001). Urinary
sodium,
potassium, and blood pressure were not affected. This study demonstrates for the first time that sesame supplementation in humans reduces the plasma and urinary levels of
20-HETE, likely via inhibition of CYP4F2 by sesame
lignans. These results suggest that sesame
lignans could be used for the investigation of potential roles of
20-HETE in humans.